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1  |  INTRODUCTION
Parkinson’s disease (PD) is diagnosed when bradykinesia oc-
curs along with rigidity or tremor, with consideration of addi-
tional supporting and exclusionary features (Hughes, Daniel, 
Kilford, & Lees, 1992; Postuma, Berg, et al., 2015). However, 
patients frequently report having had symptoms for years be-
fore the diagnosis (Gaenslen et al., 2014) and database analy-
ses have shown that a number of clinical features occur more 
frequently in patients with a later diagnosis of PD than con-
trols (Schrag, Horsfall, Walters, Noyce, & Petersen, 2015). 
Whilst it is now accepted that a long prodromal phase can 
exist, the progression of clinical features and the underlying 
pathological correlates during this phase are poorly under-
stood, and reliably identifying people in this phase remains a 
challenge (Berg et al., 2015). Neuropathological studies sug-
gest that at the time of diagnosis there has been significant 
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Abstract
Whilst the diagnosis of Parkinson’s disease (PD) relies on the motor triad of bradyki-
nesia, rigidity and tremor, the underlying pathological process starts many years be-
fore these signs are overt. In this prodromal phase of PD, a diverse range of non- motor 
and motor features can occur. Individually they do not allow a diagnosis of PD, but 
when considered together, they reflect the gradual development of the clinical syn-
drome. Different subgroups within the prodromal phase may exist and reflect different 
underlying pathology. Here, we summarise the evidence on the prodromal phase of 
PD in patient groups at increased risk of PD with well described prodromal features: 
patients with idiopathic rapid eye movement sleep behaviour disorder, patients with 
idiopathic anosmia and families with monogenic mutations that are closely linked to 
PD pathology. In addition, we discuss the information on prodromal features from 
ongoing studies aimed at detecting prodromal PD in the general population. It is likely 
that better delineation of the clinical prodromes of PD and their progression in these 
high- risk groups will improve understanding of the underlying pathophysiology.
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neuronal loss in the substantia nigra (Braak et al., 2003; 
Greffard et al., 2006) and within 4 years of diagnosis, there 
is almost complete loss of dopamine terminals in the dorsal 
putamen (Kordower et al., 2013). Through extrapolation of 
these data, it has been estimated that the disease process, in 
the brain at least, has been developing for 5 to 10 years be-
fore diagnosis (Chu, Buchman, Olanow, & Kordower, 2018; 
Fearnley & Lees, 1991; Greffard et al., 2006). Understanding 
the clinical and pathophysiological aspects of this prodromal 
phase of PD is a key challenge in PD research to enable ear-
lier diagnosis, investigation of the pathophysiological cas-
cade and, ultimately, disease- modifying treatment.
The Oxford English Dictionary defines a prodrome as “a 
symptom or sign, or a set of symptoms or signs, that is char-
acteristic or premonitory of the onset of a disease; (also) an 
early phase of a disease in which its symptoms or signs are 
mild or non- specific” (OED, 2018). Whilst this definition 
applies to what is currently known of the prodromal phase 
of PD, a range of different combinations of symptoms and 
clinical signs can occur. Individually they do not allow a di-
agnosis of PD, but when considered together, they reflect the 
gradual development of the clinical syndrome. Research cri-
teria have been developed based on a combination of such 
features (Berg et al., 2015). However, the combination of dif-
ferent symptoms and signs may differ between individuals 
and may reflect different disease subgroups.
Here, we summarise the evidence on the prodromal phase 
of PD in patient groups at increased of PD with well de-
scribed prodromal features: patients with idiopathic rapid eye 
movement (REM) sleep behaviour disorder (RBD), patients 
with idiopathic anosmia and families with monogenic mu-
tations that are closely linked to PD pathology, in particular 
the Leucine- rich repeat kinase 2 gene (LRRK2) and glucoce-
rebrosidase gene (GBA). We also discuss the information on 
prodromal features from ongoing studies aimed at detecting 
prodromal PD in the general population.
2 |  REM SLEEP BEHAVIOUR 
DISORDER
RBD is a parasomnia in which there is loss of muscle atonia 
with accompanying enactment of vivid dreams during the 
REM phase of sleep. These dream enactments can include 
vocalisation (including shouting and swearing) and com-
plex motor behaviours that can cause significant injury to 
the patient or their bed- partner. It typically occurs in older 
men (mean age at onset 50–65). An accurate diagnosis does 
not rest on the history alone, but requires polysomnography 
(PSG), with EEG recording to exclude REM sleep- related 
seizure disorders or other non- REM parasomnias, and EMG 
to accurately record muscle tone during sleep (Boeve et al., 
2007; Howell & Schenck, 2015).
RBD is closely linked to PD (and other synucleinopathies 
like dementia with Lewy bodies (DLB) and multiple system 
atrophy (MSA)) (Högl, Stefani, & Videnovic, 2017; Schenck, 
Boeve, & Mahowald, 2013): RBD frequently occurs in pa-
tients with PD, DLB or MSA with no prior sleep disorder 
(Boeve, Silber, Ferman, Lucas, & Parisi, 2001; Vetrugno 
et al., 2004). In addition, almost all people with idiopathic 
RBD develop one of these three conditions with extended 
follow- up (Iranzo et al., 2014). Neuropathological studies 
of individuals with RBD and no diagnosis of other neurode-
generative disease reveal α- synuclein deposits (Boeve et al., 
2007; Vilas et al., 2016). Interestingly, in RBD the patho-
logical changes are marked in the locus coeruleus and there 
is significant cholinergic and catecholaminergic loss as op-
posed to the predominant dopaminergic loss in PD (Dugger 
et al., 2012; Gaig & Tolosa, 2009), suggesting a possible 
alternative sequence of pathological events compared to PD 
without RBD.
PD and RBD also share similarities on imaging studies. 
MRI studies have shown very similar patterns of micro-
structural damage or altered diffusion patterns in RBD and 
PD (Barber, Klein, Mackay, & Hu, 2017; Heim, Krismer, 
De Marzi, & Seppi, 2017; Pyatigorskaya et al., 2017). 
Transcranial sonography (TCS) identifies increased echoge-
nicity in the area of the substantia nigra in around 10% healthy 
controls, 90% of PD and 36%–50% RBD (Iranzo et al., 2010; 
Li, He, Liu, & Chen, 2016). Dopamine transporter single 
photon emission tomography (DAT- SPECT) in RBD cohorts 
point towards this test’s utility as a marker of impending con-
version to overt Parkinsonism (Högl et al., 2017).
As well as the sleep disorder, the RBD prodrome of PD 
includes objective motor and non- motor deficits, with im-
paired balance (Chen et al., 2014), abnormal gait (Alibiglou, 
Videnovic, Planetta, Vaillancourt, & MacKinnon, 2016; 
Videnovic et al., 2013) and other fine and gross motor slowing 
(Postuma, Gagnon, Vendette, & Montplaisir, 2009). Postuma 
et al. demonstrated a significant motor difference in individu-
als with RBD who went on to develop PD compared to those 
who remained with “isolated RBD”: through longitudinal 
semi- quantitative motor assessments, the two groups devi-
ated around 4 years before a PD diagnosis in UPDRS motor 
scores, rigidity, gait difficulties and limb bradykinesia. With 
more objective markers, such as the Purdue pegboard, motor 
differences were detectable over 8 years prior to diagnosis 
(Postuma, Lang, Gagnon, Pelletier, & Montplaisir, 2012). 
In another 10- year prospective study in an RBD cohort, ab-
normal colour vision, anosmia and mild motor dysfunction 
were all strongly predictive of conversion to PD (Postuma, 
Gagnon, Bertrand, Génier Marchand, & Montplaisir, 2015). 
Erectile difficulty and constipation were also more common 
in the baseline assessments of the same cohort (Postuma 
et al., 2009). Fereshtehnejad et al. also found that there was 
a highly significant difference in olfactory loss in the RBD 
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cohort who converted to PD (75%) compared to those who did 
not (48%, p < 0.004) (Fereshtehnejad et al., 2017). Further 
linking RBD and anosmia as prodromal markers, Mahlknecht 
et al. found that patients with RBD who converted to PD or 
DLB within 4 years had significantly worse olfactory func-
tion at baseline than healthy controls, and were in the same 
range of smell performance as the PD patients (Mahlknecht 
et al., 2015). However, although anosmia is more common in 
RBD cases than controls, it does not appear to be a progres-
sive feature in RBD, and in a study by Iranzo et al. (2013), the 
differences in smell between the RBD and control groups did 
not change over 4 years of longitudinal follow- up. Cognitive 
dysfunction has been recognised in RBD, although whether 
this represents the prodromal phase of PD or DLB is a matter 
of debate (Génier Marchand, Montplaisir, Postuma, Rahayel, 
& Gagnon, 2017; Youn et al., 2016), and patients with con-
current PD and RBD have significantly more cognitive dys-
function than those with PD without RBD (Lin & Chen, 
2018). When applying the MDS prodromal criteria, which 
combine a range of clinical and biomarker findings, to a 
PSG- confirmed RBD cohort of whom nearly 40% converted 
to established PD, the sensitivity of the criteria in the year 
prior to the diagnosis of PD was 100%; excluding RBD from 
the analysis (with the associated likelihood ratio of 130), 
the specificity was 96.4% with a positive predictive ratio of 
87.5%. The sensitivity, however, fell to 14.6% without RBD 
(Fereshtehnejad et al., 2017). Together these findings suggest 
that patients with RBD also develop a variety of other prodro-
mal features before converting to clinical PD. However, with 
a highly variable duration of RBD prior to conversion to PD, 
the determinants and markers of progression and conversion 
from RBD to PD remain to be finalised.
3 |  IDIOPATHIC ANOSMIA
Chronic anosmia or hyposmia can be caused by a variety 
of conditions: congenital, post- traumatic, post- infectious, 
idiopathic and related to neurodegeneration (Boesveldt et al., 
2017). Anosmia is a common finding, affecting up to 20% 
of the population and is associated with ageing (Boesveldt 
et al., 2017). Anosmia is also a common finding in PD, with 
the majority of PD patients having impaired or absent smell 
(Ross et al., 2008). Underpinning these observations is neu-
ropathological evidence that suggests that the olfactory bulb 
is affected early in the disease process, creating an anatomical 
link between the two conditions (Braak et al., 2003; Pearce, 
Hawkes, & Daniel, 1995; Ubeda- Bañon, Saiz- Sanchez, de la 
Rosa- Prieto, & Martinez- Marcos, 2014).
Patients commonly report that they lost their sense of 
smell years before the diagnosis of PD (Haehner, Hummel, 
& Reichmann, 2014), and there is considerable evidence for 
olfactory loss as a prodromal feature of PD. In a study of 
361 individuals with a first degree relative with PD and no 
diagnosed neuropsychological or olfactory disorder, those 
with impaired olfaction (defined as the lowest 10% Z- scores 
by age group and gender) had an increased risk of develop-
ing PD after 2 years of follow up. The hyposmic group also 
had an increased rate of abnormal [123I]β- CIT SPECT com-
pared to those with normal smell (Ponsen et al., 2004). In the 
Health, Aging and Body Composition study, poor olfaction 
using the brief smell identification test (BSIT) predicted the 
onset of PD with a hazard ratio of 4.8 for the lowest tertile 
(≤8/12 correct responses) compared to the highest tertile 
(≥11/12 correct responses) adjusting for sex and race over 
an average follow up of 9.8 years (Chen et al., 2017). In the 
Honolulu- Asia Aging Study, smell loss (again tested with the 
BSIT — with a lower cut- off of ≤5/12 correct responses) was 
associated with a 5- fold increased risk of PD at 4 years fol-
low- up, when adjusted for age and other factors that affect 
PD risk (cigarette smoking, coffee consumption and consti-
pation) (Ross et al., 2008). Interestingly, they found that this 
increased risk was not seen at follow- up more than 4 years 
without conversion to PD. This raises the possibility that an-
osmia as part of a Parkinson’s prodrome may only develop 
within 4 years of manifestation of PD.
The Parkinson At- Risk Study (PARS) has utilised this in-
creased risk of PD in people with olfactory loss to further 
study other aspects of the prodrome of PD. This multicentre 
North American study (Siderowf et al., 2012) recruited 669 
adults >50 years with hyposmia (defined as <15th centile 
using the UPSIT) and 4330 with intact smell. At baseline, 
constipation (defined as <1 bowel movement per day) was 
more frequent in those with hyposmia but common in both 
groups (21% vs. 16%) as were anxiety (state 19% vs. 14%, 
trait 23% vs. 17%) and depression (19% vs. 11%). Reported 
features of RBD were also more common in those with hy-
posmia (12% vs. 7% for ≥1 limb/body movement per week; 
3% vs. 1% violent movements/week). In follow- up reports, 
whilst the hyposmic cohort did not have worse UPDRS scores 
than the normosmic controls, a significantly greater propor-
tion had DAT deficit using [123I]β- CIT SPECT (11% vs. 1%). 
Of the hyposmics with abnormal DAT scans, other prodro-
mal symptoms were common: RBD, subtle motor symptoms 
or constipation (Jennings et al., 2014). Furthermore, in the 
hyposmic group, DAT deficit was strongly associated with 
conversion to PD within 4 years with a relative risk of 17.5 
compared to those with indeterminate or no DAT deficit 
(Jennings et al., 2017).
In another study using olfaction as one key identifier, the 
Tübingen Evaluation of Risk Factors for Early Detection of 
Neurodegeneration (TREND) study has followed nearly 700 
“healthy” older adults (50–85 years) with prodromal markers 
(impaired olfaction, depression or RBD) with biannual as-
sessments. Those with anosmia had significantly fewer other 
prodromal features than the other two groups at baseline. 
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Marked differences were reported in the rates of constipation 
(7% in the anosmic group compared to 22% and 25% in the 
RBD and depression groups), insomnia other than RBD (34% 
vs. 65% and 53%), visuospatial perception (2.2% vs. 12% and 
14%), orthostatic hypotension (13% vs. 33% and 25%) and 
cognitive complaints (bradyphrenia: 24% vs. 36% and 46%, 
word recall: 37% vs. 60% and 53%) (Gaenslen et al., 2014). 
Of the 10 participants in the TREND study who converted 
to PD within 6 years, nine had hyposmia at baseline, and all 
had probable (not PSG- confirmed) RBD (although it should 
be noted that this study was enriched for both these markers).
Whilst olfactory loss is clearly an important component 
of the prodrome of PD in a large proportion of patients with 
PD, there is a (potentially large) proportion of individuals 
with idiopathic anosmia not linked to neurodegeneration. The 
above studies provide important information on anosmia in 
the prodrome of PD but further examination and longitudinal 
assessment of people with idiopathic anosmia evaluated for 
all known causes of hyposmia will be needed to determine 
the boundaries and characteristics of anosmia as a prodromal 
PD phenotype.
Overall, however, whilst not all patients with PD have 
hyposmia or RBD even when the diagnosis is established 
(Haehner et al., 2014; Zhang, Sun, Wang, Tang, & Xie, 
2017), both the detection of RBD and hyposmia offers the 
opportunity to create clinical cohorts to study the biological, 
pathological and biomarker correlates between RBD or idio-
pathic anosmia and neurodegeneration.
4 |  LRRK2
Although only a small proportion of patients with PD have 
a monogenic cause of PD, compared to other risk factors 
family history has one of the strongest associations with PD 
(Noyce et al., 2012). A number of cohort studies of PD there-
fore also include an arm to longitudinally study first- degree 
family members of patients with PD, including the PPMI, 
OPDC and Tracking Parkinson’s/PRoBaND studies (Malek 
et al., 2015; Parkinson Progression Marker Initiative, 2011; 
Szewczyk- Krolikowski et al., 2014). However, whilst only 
a small minority of individuals with PD have a monogenic 
cause of PD, those with mutations known to confer an in-
creased risk of PD provide the clearest information on the 
development of prodromal features. In the US and European 
studies, the commonest cause of autosomal dominant PD is 
a mutation in the LRRK2 gene, accounting for about 1% of 
all PD cases (Healy et al., 2008). This is a complex gene 
whose role in neurodegeneration is not completely under-
stood (Kalia et al., 2015). Penetrance is incomplete and 
carriers of the mutation have an age- dependent risk of PD 
that reaches around 25%–42% at 80 years (Lee et al., 2017; 
Marder et al., 2015). Once manifest, the motor features of 
LRRK2- PD are largely indistinguishable from idiopathic 
PD, and examination of carriers of LRRK2 mutations there-
fore provide a useful model for prodromal PD. In the last 
few years, several longitudinal cohort studies of LRRK2 
carriers have been published (Mestre et al., 2018; Mirelman 
et al., 2015, 2018; Pont- Sunyer et al., 2017; Sierra et al., 
2013, 2017). However, unlike in “idiopathic” PD, anos-
mia has been reported to be infrequent in LRRK2 PD cases 
(Marras et al., 2016) and also in LRRK2 carriers (Mestre 
et al., 2018; Mirelman et al., 2015; Pont- Sunyer et al., 2017). 
On the other hand, LRRK2 carriers had more errors on the 
Farnsworth- Munsell 100 Hue test of colour discrimination 
than healthy controls, and LRRK2 PD patients compared to 
idiopathic PD patients (Marras et al., 2016). One study re-
ported that constipation was a more common feature among 
LRRK2 carriers than controls (Mirelman et al., 2018), but 
other autonomic, affective and cognitive functions were not 
significantly different across most studies reviewed. Motor 
dysfunction measured on the UPDRS III was not signifi-
cantly different in a Spanish LRRK2 cohort in those who 
converted to PD compared to non- converters at baseline, al-
though in those that went on to convert to PD within 4 years 
there was significant worsening of the UPDRS III scores 
from a mean of 9.3 at baseline to 25 compared to 0.8 to 1.6 
in the non- converting group (although the number of con-
verters was small) (Sierra et al., 2017).
With the generation of a mouse model with LRRK2 
R1441C mutation, Giesert et al. have shown prodromal fea-
tures in old- age mice in several measures of gait analysis, 
anxiety tests and olfaction (Giesert et al., 2017). This work 
shows that animal models of the prodromal phase of PD can 
be established, and as the biology of other prodromes is re-
vealed, laboratory models can be tailored to explore these 
phenotypes.
5 |  GBA
Glucocerebrosidase is a lysosomal enzyme encoded by 
the GBA gene. Homozygous GBA mutations cause type 1 
Gaucher’s disease (GD), the commonest lysosomal stor-
age disorder (McNeill et al., 2012), and patients with 
GD are at increased risk of PD. About 5%–10% of PD 
patients have mutations in the GBA1 gene, with a higher 
proportion in certain populations (particularly Ashkenazi 
Jews) (Schapira, 2015). The risk of conversion to PD in 
heterozygous carriers of a genetic mutation is similar to 
LRRK2 carriers, with approximately 30% developing PD at 
80 years (Anheim et al., 2012). This risk lies between that 
associated with rare but highly pathogenic mutations (such 
as in LRRK2, SNCA etc.) and mutations that are common 
but confer minimal additional risk influence (as detected 
through genome- wide association studies). In patients 
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with established PD who are heterozygous for GBA mu-
tations the clinical features are similar to those with idi-
opathic PD, but a slightly earlier onset has been reported, 
and non- motor symptoms including RBD and cognitive 
impairment occur more commonly and earlier than in idi-
opathic PD (Balestrino & Schapira, 2018). Compared to 
healthy controls, both GD patients and non- GD carriers of 
GBA have slightly worse smell, cognition and motor im-
pairment on the UPDRS III motor scale (Gatto et al., 2016; 
McNeill et al., 2012). In GBA carriers without established 
PD, Beavan et al. reported not only a higher rate of familial 
occurrence of PD than controls (GD 16.7%, GBA heterozy-
gous 7.1%, controls 0% (p = 0.3)), but also worse olfac-
tory function, more autonomic features (using the Unified 
Multiple Systems Atrophy Rating scale (UMSARS)), 
worse cognitive scores (using the Montreal Cognitive 
Assessment) and worse UPDRS II and III scores with 
significant evidence of progression over 2 years (Beavan 
et al., 2015). Ongoing follow- up of this cohort will be es-
sential to examine progression rates from the onset of the 
prodromal phase through to established PD.
6 |  GENERAL POPULATION
Several studies are also aiming to identify people with 
prodromal PD in the general population in order to more 
robustly define the prodromal features of PD outside of se-
lected risk groups. Using different methods, these studies 
aim to enrich the general population for risk of PD using 
combinations of a variety of non- motor and motor features, 
clinical features, and imaging biomarkers (DAT- SPECT, 
TCS and/or MRI). These studies include the Prospective 
validation of Risk factors for Idiopathic Parkinson’s 
Syndromes (PRIPS) study (Berg et al., 2013), TREND 
(Gaenslen et al., 2014) and PREDICT- PD (Noyce et al., 
2014). Whilst only longitudinal follow- up will determine 
the association of the tested variables with development of 
clinical PD, preliminary results are already available. In a 
combined analysis of the TREND and PRIPS studies, those 
converting to PD and those with high probability according 
to the MDS research criteria for prodromal PD had higher 
rates than those who did not of RBD, anosmia, mild motor 
symptoms, constipation and erectile dysfunction (Pilotto 
et al., 2017). The PREDICT- PD study uses an online ap-
proach to identify increased risk of PD using a combination 
of risk and prodromal factors. RBD, anosmia and motor 
dysfunction as well as abnormalities on DAT- SPECT and 
TCS were significantly greater in the higher than the lower- 
risk group (Noyce et al., 2017). These general population 
cohorts are likely to represent an amalgamation of different 
patient groups and will provide insight into the heterogene-
ity of PD even in this prodromal phase.
7 |  CONCLUSIONS
Retrospective studies and examination of newly diagnosed 
patients with PD have suggested a long prodromal phase 
of PD, beginning several years before definite features of 
clinical PD. There is now increasing information from cross- 
sectional and prospective studies in cohorts at increased risk 
of PD, particularly those with RBD and anosmia and carriers 
of PD- related mutations. In addition, approaches to combine 
several risk factors are increasingly providing insight into the 
identification and presentation of those in the earliest phases 
of PD. It is likely that better recognition of the clinical pro-
dromes of PD will provide further understanding of their un-
derlying pathophysiology.
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